BioTrove and partner win NIH grant for better cancer genetic test

By Mass High Tech Staff

Biomed Notebook: A Darwinian view of life sciences [February 13, 2009]

Experts offer survival strategies at MHT BioForum [February 5, 2009]

Salmon help biotechs in blood and spinal regeneration market [December 19, 2008]

Biotrove plans to pull $75M IPO registration [December 18, 2008]

Biotech company BioTrove Inc. reports it has won a two-year National Institutes of Health (NIH) grant along with partner Gene Express Inc. of Wilmington, N.C., to further their proposed novel research of genetic biomarkers for lung cancer.

According to Woburn-based BioTrove, the research project will combine BioTrove’s OpenArray nanofluidic polymerase chain reaction (PCR) technology platform with the Gene Express standards method for accurate and consistent PCR measurement.

The research will be conducted at Mount Sinai School of Medicine, to create a standardized genetic profiling test for indicators of lung cancer risk, according to BioTrove officials. Once created, the combined testing tool will be evaluated independently at the Harvard School of Dental Medicine and the Stanford University Genome Technology Center.

BioTrove offers two technology platforms, including the RapidFire systems and its OpenArray tools used in genomic research for science-related industries. In April the company filed for a $75 million initial public offering. BioTrove generated $4.8 million in revenue last year and posted a net loss of nearly $16 million, according to the filing.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.